Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Delpón

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|August 4, 2025
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?Juan Tamargo, Eva Delpón
Expert Opinion on Drug Safety|June 26, 2012
Drug-induced atrial fibrillationJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Investigational Drugs|December 8, 2018
New drugs in preclinical and early stage clinical development in the treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Cardiovascular Therapy|August 4, 2011
Ranolazine: an antianginal drug with antiarrhythmic propertiesJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|May 16, 2021
Sex-related differences in the pharmacological treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|January 7, 2026
SGLT2 inhibitors: Do they have antiarrhythmic properties?Ricardo Caballero, Juan Tamargo, Eva Delpón
Cardiovascular Drugs and Therapy|January 27, 2018
New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System InhibitorsJuan Tamargo, Ricardo Caballero, Eva Delpón
Current Medicinal Chemistry|February 3, 2004
Pharmacological approaches in the treatment of atrial fibrillationJuan Tamargo, Ricardo Caballero, Eva Delpón
Drug Safety|January 13, 2022
Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of CardiotoxicityJuan Tamargo, Ricardo Caballero, Eva Delpón
Drug Safety|January 12, 2015
Cancer chemotherapy and cardiac arrhythmias: a reviewJuan Tamargo, Ricardo Caballero, Eva Delpón
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
European Heart Journal. Cardiovascular Pharmacotherapy|August 4, 2025
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?Juan Tamargo, Eva Delpón
Expert Opinion on Drug Safety|June 26, 2012
Drug-induced atrial fibrillationJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Investigational Drugs|December 8, 2018
New drugs in preclinical and early stage clinical development in the treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Cardiovascular Therapy|August 4, 2011
Ranolazine: an antianginal drug with antiarrhythmic propertiesJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|May 16, 2021
Sex-related differences in the pharmacological treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|January 7, 2026
SGLT2 inhibitors: Do they have antiarrhythmic properties?Ricardo Caballero, Juan Tamargo, Eva Delpón
Cardiovascular Drugs and Therapy|January 27, 2018
New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System InhibitorsJuan Tamargo, Ricardo Caballero, Eva Delpón
Current Medicinal Chemistry|February 3, 2004
Pharmacological approaches in the treatment of atrial fibrillationJuan Tamargo, Ricardo Caballero, Eva Delpón
Drug Safety|January 13, 2022
Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of CardiotoxicityJuan Tamargo, Ricardo Caballero, Eva Delpón
Drug Safety|January 12, 2015
Cancer chemotherapy and cardiac arrhythmias: a reviewJuan Tamargo, Ricardo Caballero, Eva Delpón
Pageof 9